Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Exp Dermatol ; 33(4): e15069, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38568090

RESUMO

Topicals and chemical peels are the standard of care for management of facial hyperpigmentation. However, traditional therapies have come under recent scrutiny, such as topical hydroquinone (HQ) has some regulatory restrictions, and high concentration trichloroacetic acid (TCA) peel pose a risk in patients with skin of colour. The objective of our research was to identify, investigate and elucidate the mechanism of action of a novel TCA- and HQ-free professional-use chemical peel to manage common types of facial hyperpigmentation. Using computational modelling and in vitro assays on tyrosinase, we identified proprietary multi-acid synergistic technology (MAST). After a single application on human skin explants, MAST peel was found to be more effective than a commercial HQ peel in inhibiting melanin (histochemical imaging and gene expression). All participants completed the case study (N = 9) without any adverse events. After administration of the MAST peel by a dermatologist, the scoring and VISIA photography reported improvements in hyperpigmentation, texture and erythema, which could be linked to underlying pathophysiological changes in skin after peeling, visualized by non-invasive optical biopsy of face. Using reflectance confocal microscopy (VivaScope®) and multiphoton tomography (MPTflex™), we observed reduction in melanin, increase in metabolic activity of keratinocytes, and no signs of inflammatory cells after peeling. Subsequent swabbing of the cheek skin found no microbiota dysbiosis resulting from the chemical peel. The strong efficacy with minimum downtime and no adverse events could be linked to the synergistic action of the ingredients in the novel HQ- and TCA-free professional peel technology.


Assuntos
Hidroquinonas , Hiperpigmentação , Melaninas , Humanos , Hiperpigmentação/tratamento farmacológico , Pele , Biologia Computacional , Biópsia
3.
J Am Acad Dermatol ; 84(6): 1667-1676, 2021 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-32771543

RESUMO

Neurofibromatosis type 1 is the most common neurocutaneous syndrome, with a frequency of 1 in 2500 persons. Diagnosis is paramount in the pretumor stage to provide proper anticipatory guidance for a number of neoplasms, both benign and malignant. Loss-of-function mutations in the NF1 gene result in truncated and nonfunctional production of neurofibromin, a tumor suppressor protein involved in downregulating the RAS signaling pathway. New therapeutic and preventive options include tyrosine kinase inhibitors, mTOR inhibitors, interferons, and radiofrequency therapy. This review summarizes recent updates in genetics, mutation analysis assays, and treatment options targeting aberrant genetic pathways. We also propose modified diagnostic criteria and provide an algorithm for surveillance of patients with neurofibromatosis type 1.


Assuntos
Neurofibromatose 1/diagnóstico , Neurofibromina 1/genética , Inibidores de Proteínas Quinases/uso terapêutico , Terapia por Radiofrequência/métodos , Neoplasias Cutâneas/genética , Terapia Combinada/métodos , Análise Mutacional de DNA , Diagnóstico Diferencial , Humanos , Mutação com Perda de Função , Neurofibromatose 1/genética , Neurofibromatose 1/terapia , Neurofibromina 1/metabolismo , Inibidores de Proteínas Quinases/farmacologia , Transdução de Sinais/genética , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/terapia , Serina-Treonina Quinases TOR/antagonistas & inibidores , Resultado do Tratamento , Proteínas ras/metabolismo
4.
J Dermatolog Treat ; 31(5): 444-445, 2020 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-32347761

RESUMO

Due to the COVID-19 pandemic, planned medical and surgical activities are being postponed. For the dermatology community, this interruption to the healthcare system can lead to delays in the diagnosis and treatment of melanoma. Neglecting melanoma during this crisis can result in increased mortality, morbidity and healthcare costs. With the COVID-19 pandemic evolving and no clear solutions in sight, it is time for the prospective evaluation of teledermatology. However, dermatologists should be cautious and continue seeing patients with pigmented lesions in person due to the necessity of early surgical intervention.


Assuntos
Infecções por Coronavirus/epidemiologia , Dermatologia/métodos , Melanoma/diagnóstico , Melanoma/terapia , Pneumonia Viral/epidemiologia , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/terapia , Betacoronavirus , COVID-19 , Diagnóstico Tardio , Procedimentos Cirúrgicos Dermatológicos , Custos de Cuidados de Saúde , Humanos , Pandemias , Estudos Prospectivos , SARS-CoV-2 , Taxa de Sobrevida , Telemedicina , Tempo para o Tratamento
5.
Am J Clin Dermatol ; 21(3): 393-399, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-32002848

RESUMO

A fixed drug eruption (FDE) is a relatively common reaction associated with more than 100 medications. It is defined as a same-site recurrence with exposure to a particular medication. The primary approach and treatment for all types of FDEs are to identify and remove the causative agent, often accomplished by a thorough history of medication and other chemical exposures, and possibly prior episodes. The most common category of FDE, localized FDE, whether bullous or non-bullous, is self-limited. Although one can confirm the causative agent using oral challenge testing, it is not recommended due to the risk of severe exacerbation or possible generalization; patch testing is now preferred. Bullous FDE may resemble erythema multiforme. Treatment of localized FDE includes medication removal, patient counseling, and symptomatic relief. Failure to remove the causative agent in localized FDE can lead to recurrence, which is associated with increased inflammation, hyperpigmentation, and risk of a potentially lethal generalized bullous FDE (GBFDE), which may resemble Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Distinguishing GBFDE from SJS and TEN is salient and will be stressed: GBFDE has more rapid onset in 1-24 h rather than in weeks, less or no mucosal involvement, less or no systemic involvement, and a tendency for a more favorable prognosis; however, recent experience suggests it may be just as life-threatening. This review will provide a comprehensive update and approach to diagnosis and management.


Assuntos
Toxidermias/diagnóstico , Cuidados Paliativos/métodos , Aconselhamento , Diagnóstico Diferencial , Toxidermias/etiologia , Toxidermias/mortalidade , Toxidermias/terapia , Eritema Multiforme/diagnóstico , Humanos , Testes do Emplastro , Prognóstico , Recidiva , Índice de Gravidade de Doença , Pele/efeitos dos fármacos , Pele/patologia , Fatores de Tempo
6.
J Cosmet Dermatol ; 18(3): 700-702, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-30801957

RESUMO

Pigmentary demarcation lines (PDLs) are physiological abrupt transitions between hyperpigmented and lighter skin, a common and sometimes troubling feature of normal skin. They are seen in a majority of dark-complexioned women and a substantial percentage of light-complexioned ones too. We review this salient finding and approaches to its management.


Assuntos
Transtornos da Pigmentação/diagnóstico , Complicações na Gravidez/diagnóstico , Pigmentação da Pele/fisiologia , Administração Cutânea , Fármacos Dermatológicos/administração & dosagem , Diagnóstico Diferencial , Feminino , Humanos , Lasers , Terapia com Luz de Baixa Intensidade/instrumentação , Terapia com Luz de Baixa Intensidade/métodos , Masculino , Transtornos da Pigmentação/etiologia , Transtornos da Pigmentação/terapia , Gravidez , Complicações na Gravidez/etiologia , Complicações na Gravidez/terapia
8.
Dermatol Clin ; 36(1): 5-10, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29108546

RESUMO

Men are interested in reducing signs of aging, while maintaining a masculine appearance. A chief concern among men is maintenance of scalp hair. Men are also concerned with reducing under eye bags and dark circles. The concern of feminization is of significant importance. Neuromodulators remain the most common cosmetic procedure performed in men. Men often prefer a reduction in facial rhytids, as opposed to elimination of the lines. Softening facial lines in men is meant to maintain an appearance of wisdom, without appearing fragile. Men also wish to maintain a taut jawline and a slim waist and reduce breast tissue.


Assuntos
Técnicas Cosméticas , Estética/psicologia , Envelhecimento da Pele , Face , Cabelo , Humanos , Masculino
10.
Am J Clin Dermatol ; 17(5): 485-489, 2016 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-27566177

RESUMO

Shiitake mushroom dermatitis is a cutaneous reaction caused by the consumption of raw or undercooked shiitake mushrooms. Symptoms include linear erythematous eruptions with papules, papulovesicles or plaques, and severe pruritus. It is likely caused by lentinan, a heat-inactivated beta-glucan polysaccharide. Cases were initially reported in Japan but have now been documented in other Asian countries, North America, South America, and Europe, as this mushroom is now cultivated and consumed worldwide. Shiitake mushroom dermatitis may result from mushroom ingestion or from handling, which can result in an allergic contact dermatitis.


Assuntos
Dermatite/etiologia , Hipersensibilidade Alimentar/etiologia , Cogumelos Shiitake/química , Culinária , Dermatite/patologia , Dermatite Alérgica de Contato/etiologia , Dermatite Alérgica de Contato/patologia , Hipersensibilidade Alimentar/patologia , Humanos , Lentinano/efeitos adversos
11.
Dermatol Online J ; 18(4): 4, 2012 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-22559019

RESUMO

Idiopathic atrophoderma of Pasini and Pierini is a disorder of dermal atrophy. There is a female predominance and almost never does the condition present at birth. Histopathological examination reveals attenuated dermis. We report a case of a healthy male born with a plaque of idiopathic atrophoderma of Pasini and Pierini.


Assuntos
Atrofia/congênito , Atrofia/patologia , Dermatopatias/congênito , Dermatopatias/patologia , Humanos , Lactente , Masculino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...